Travere Therapeutics, Inc. TVTX Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s change in accrued liabilities?
- Travere Therapeutics, Inc. (TVTX) reported change in accrued liabilities of -$20.9M in Q1 2026.
- How has Travere Therapeutics, Inc.'s change in accrued liabilities changed year-over-year?
- Travere Therapeutics, Inc.'s change in accrued liabilities decreased by 119.1% year-over-year, from -$9.54M to -$20.9M.
- What is the long-term trend for Travere Therapeutics, Inc.'s change in accrued liabilities?
- Over 2 years (2021 to 2025), Travere Therapeutics, Inc.'s change in accrued liabilities has grown at a 31.5% compound annual growth rate (CAGR), from $16.68M to $28.84M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.